Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Non-Current Liabilities (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Total Non-Current Liabilities data on record, last reported at $891648.0 in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 3.5% year-over-year to $891648.0; the TTM value through Sep 2025 reached $891648.0, up 3.5%, while the annual FY2024 figure was $872989.0, 19.25% down from the prior year.
  • Total Non-Current Liabilities reached $891648.0 in Q3 2025 per GANX's latest filing, down from $940886.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.6 million in Q4 2021 and bottomed at $815921.0 in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: rose 25.43% in 2021, then tumbled 43.76% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.6 million in 2021, then crashed by 32.22% to $1.1 million in 2022, then decreased by 1.23% to $1.1 million in 2023, then dropped by 19.25% to $872989.0 in 2024, then rose by 2.14% to $891648.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $891648.0 in Q3 2025, $940886.0 in Q2 2025, and $815921.0 in Q1 2025.